Trinity Biotech (TRIB) has obtained an additional $4M in debt financing from its primary lender, Perceptive Advisors. The additional liquidity will support both the continued development of Trinity Biotech’s innovative continuous glucose monitoring technology and the Company’s comprehensive transformation plan. The Company continues to focus much of its growth efforts around its CGM technology, especially given the previously announced positive results from its most recent pre-pivotal trial. The Company’s comprehensive transformation plan is focused on increasing profitability and cash-flow generation across the Company’s portfolio of operating businesses. Since the announcement of the transformation plan, the Company has taken steps to increase operational efficiencies with a view to increasing the Company’s financial strength and will continue to review and manage the optimization of its business portfolio and capital structure.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TRIB:
- Trinity Biotech’s CGM System Shows Breakthrough Improvements
- Trinity Biotech reports findings from latest pre-pivotal trial on CGM system
- Trinity Biotech Secures Continued U.S. Government Funding for HIV Testing
- 3 Penny Stocks to Watch Now, 1/30/25
- Trinity Biotech Faces Uncertainty Over U.S. Executive Order and Loan Eligibility